[Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre<sup>®</sup> Tablets), a selective fibroblast growth factor receptor (FGFR) inhibitor].

Kabu, Koki; Takei, Satoko; Kondo, Midori; Kitazawa, Kazuya; Harada, Takashi

[Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre^® Tablets), a selective fibroblast growth factor receptor (FGFR) inhibitor].

Kabu, Koki; Takei, Satoko; Kondo, Midori; Kitazawa, Kazuya; Harada, Takashi.

Affiliation

Kabu K; Medical Affairs, Incyte Biosciences Japan G.K.
Takei S; Medical Affairs, Incyte Biosciences Japan G.K.
Kondo M; Medical Affairs, Incyte Biosciences Japan G.K.
Kitazawa K; Medical Affairs, Incyte Biosciences Japan G.K.
Harada T; Medical Affairs, Incyte Biosciences Japan G.K.

Nihon Yakurigaku Zasshi ; 156(6): 392-402, 2021.

Article in Ja | MEDLINE | ID: mdl-34719574

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholangiocarcinoma Type of study: Prognostic_studies Limits: Animals / Humans Language: Ja Journal: Nihon Yakurigaku Zasshi Year: 2021 Document type: Article Country of publication: Japón

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google